(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Whale stranded off Germany for days free again - 2A coup too far: Why Benin's rebel soldiers failed where others in the region succeeded
- 3Cathay Pacific raises fuel surcharge on all flights by 34%
- 4Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- 5Pope Leo XIV calls for urgent climate action and says God’s creation is 'crying out'
- 'Euphoria' releases Season 3 photos with Zendaya, Sydney Sweeney, Jacob Elordi and others: See them
- Nurturing Hacks: Shrewdness from Experienced Mothers and Fathers
- Nestlé recalls infant formula in 49 countries. See list.
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- The most effective method to Pick The Right Speakers
- Florida has quietly become America's execution capital
- Major railway disruptions persist as Germany braces for more snow
- Relish the World: Notable Caf\u00e9s You Really want to Attempt
- Getting Your Youngsters' Future: Grasping Legacy Regulations
